Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-01

Study Completion Date

2024-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this open label clinical trial is to reduce the effects of restless leg syndrome. The main it questions it aims to answer are:

1. Reduce or eliminate the symptoms of restless leg syndrome.
2. Improve the quality of life of participants with restless leg syndrome.

Participants will be asked to apply the topical cream to the affected area 30 to 45 minutes before bedtime for 14 consecutive days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Using Cannabis to Treat Restless Legs Syndrome

NCT06863740

Restless Leg Syndrome (RLS)

RECRUITING NA

Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome

NCT00135993

Restless Legs Syndrome

COMPLETED PHASE3

Tolerability and Efficacy of CBD Extract for RLS Treatment

NCT07224932

Restless Leg Syndrome

NOT_YET_RECRUITING PHASE2

An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome

NCT00263068

Restless Legs Syndrome

COMPLETED PHASE3

Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome

NCT00136045

Restless Legs Syndrome

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Restless Leg Syndrome (RLS) is multifactorial disease state with many different potential pathophysiological mechanisms, which includes dysfunctions from the cerebral cortex and spinal cord to mechanosensitive channels at the musculoskeletal periphery.1 Most therapeutic agents' effectiveness focuses on the CNS (e.g., dopaminergic drugs) or Renshaw cells. To our knowledge, therapeutic agents that are focused on the periphery were not very effective.

This technology focuses on the peripheral musculoskeletal component of the disease and is directed at treatment modalities that correct the dysfunction of mechanosensitive channels. By combining what is known about cannabinoids activity at the transient receptor potential channel of ankyrin 1 (TRPA1)2 and the role TRPA1 plays in regulating the shape and rigidity of the surrounding membrane structure at the Piezo channels3, an effective therapy at the site of discomfort should emerge. Moreover, the lessening of membrane tension is imparted by molecules that readily penetrate the membrane4, which Chylobinoid, the topical active ingredient, is uniquely designed to do.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Restless Legs Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

therapeutic open label single group

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome

Topical of application of cream to effected area 30-45 minutes before bedtime

Group Type EXPERIMENTAL

Chylobinoid Topical Cream

Intervention Type DRUG

The topical cream is applied to the effected area to reduce or eliminate the symptoms of restless leg syndrome

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Chylobinoid Topical Cream

The topical cream is applied to the effected area to reduce or eliminate the symptoms of restless leg syndrome

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cannabidiolic acid topical cream

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with at least 3 month-course of symptomatic restless leg syndrome
* Must meet International Restless Legs Syndrome Study Group (IRLSSG) criteria of at least mild symptoms.
* Age \> 18 years, including both males and females
* Patient provides informed consent

Exclusion Criteria

* Previous operative procedure for treatment of RLS;
* Current use of TENS (transcutaneous electrical nerve stimulation or plasma exchange;
* Allergy to Cannabidiol (CBD) Cannabidiolic acid (CBDa), or any other ingredient contained in the topical cream;
* Pregnant participants (participants who have the potential for being pregnant will sign a waiver), or breast feeding;
* History of recreational substance abuse, fibromyalgia, Chronic Regional Pain Syndrome (CRPS), psychiatric history including but not limited to schizoaffective disorder, bipolar disorder, chronic depression, and suicidal ideation;
* Conditions affecting capacity and adherence to study regimen including but not limited to dementia/delirium, Alzheimer's, Down's syndrome;
* A need for elective surgery involving preoperative or postoperative analgesics or anesthetics during the study period;
* No recent cannabinoid use in the last 2 months, and no use during the study.

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No